Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is a strong and diversified medical company with a focus on innovative products and solutions in the blood and plasma industry. With stable revenue growth and plans for improvements in operating margins, the company has shown promising financial performance. While there are concerns about the decline in interventional technologies, the company's overall growth potential and solid reputation make it a solid investment option. Risk factors such as competition and fluctuations in procedure volumes are also important considerations.

Bears say

Haemonetics is facing challenges in the competitive blood center segment, reflected by the decline of 19.6% in reported revenue in the latest quarter. Despite increasing expectations for organic growth in this segment, there is still uncertainty surrounding the company's ability to compete effectively. This, combined with the fact that the plasma and hospital segments drive the majority of revenue, leads to a negative outlook on the stock.

Haemonetics (HAE) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 9 analysts, Haemonetics (HAE) has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.